Showing 35,225 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Cardiovascular disease

Reservoirs of HIV-infected cells that can't be reached by antiretroviral therapy associated with an important marker of cardiovascular disease risk

News
13 November 2020
Weight gain & lipodystrophy

Women Show Higher INSTI-Associated Weight Gain and Incident Diabetes Mellitus Than Men

Editor's pick
Infectious Disease Advisor
12 November 2020
Coronavirus

COVID-19 antibody testing for HIV positive people in the UK: HIV organisations reverse previous exclusion

Editor's pick
i-Base
11 November 2020
Improving HIV care

For PrEP to Work, Shared Doctor-Patient Decision-Making Is Key

Editor's pick
TheBodyPro
11 November 2020
People & personal stories

IAS names Birgit Poniatowski as IAS Executive Director

Editor's pick
International AIDS Society
11 November 2020

Disclosure and relationships are main concerns for gay men living with HIV – HIV update, 11 November 2020

November 2020
Hepatitis & HIV

European HIV doctors conduct their first-ever region-wide audit of services

News
11 November 2020
Undetectable viral load & treatment as prevention

U=U improves gay men's sense of self and many believe it will reduce HIV-related stigma

News
11 November 2020
Clinical trials

Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry

Editor's pick
FDA
10 November 2020
Injectable & long-acting PrEP

Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women

Editor's pick
World Health Organization
10 November 2020
Pharmaceutical industry

GlaxoSmithKline's HIV PrEP challenge looms as ViiV's long-acting drug tops Gilead's Truvada in women

Editor's pick
FiercePharma
10 November 2020
Injectable & long-acting PrEP

HIV prevention injection hailed as a “major breakthrough” for women

Editor's pick
Spotlight
10 November 2020
Drug policy & policing

Where the Biden Administration Will Stand on Drugs and Harm Reduction

Editor's pick
Filter
10 November 2020
Injectable & long-acting PrEP

ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women

Editor's pick
ViiV press release
9 November 2020
Experiences of stigma

“We forget that we're human. We are. We are human beings”: long-term HIV survivors living on society’s margins

News
9 November 2020
Health services & systems

You and your HIV healthcare team

About HIV
November 2020
Activism & civil society

The trans community organisers taking healthcare into their own hands

Editor's pick
i-D
6 November 2020
PrEP programmes & uptake

‘PrEP for Women Too’ Campaign Aims to Bring This Empowering HIV Prevention Tool to More Black and Latinx Women

Editor's pick
TheBodyPro
6 November 2020
Drug policy & policing

US voters put a major dent in the drug war — that's good

Editor's pick
The Hill
6 November 2020
Weight gain & lipodystrophy

Diabetes drug may aid weight loss in people with HIV

News
6 November 2020
Coronavirus

aidsmapCHAT: series 3, episode 1 Video

November 2020
Coronavirus

Unstable housing explains higher rates of COVID-19 in people with HIV in San Francisco

News
5 November 2020
Harm reduction

I opened the first safe consumption facility in Scotland to reduce disease and save people's lives

Editor's pick
MyPOV (video)
4 November 2020
Activism & civil society

Ten black HIV activists and influencers making an impact

Editor's pick
Terrence Higgins Trust
4 November 2020